



3 March 2015

Announcements

National Stock Exchange of Australia

PO Box 283

NEWCASTLE NSW 2300

Market Announcement – NASDAQ cross-listing

iQX Limited (NSX:IQX) (the Company) announced today that it has commenced the process to list the Company's depository receipts on the NASDAQ Capital Markets USA and upon admission will be trading under the ticker symbol "IQX". The move to the NASDAQ Capital Markets will expose the company to a greater investor base, both retail and Institutional. IQX would join a home of more than 3,500 listed companies with a market value of over \$9.1 trillion.

iQX Limited Chief Executive Officer Dr George Syrmalis said, the NASDAQ cross-listing was timely and strategic, benefiting both , our company investors, as well as the beneficiaries of our fund "IQ Series 8". *"Biotech was one of the most profitable sectors in 2014. Through Dec. 18, the S&P 500 Biotechnology Index is up 43.6% and the Nasdaq Biotechnology Index is up 36.9%. In particular biotech, has more than doubled within the composite over the past 15 years. There is great investor interest in the biotech sector at the moment; there are some interesting very early stage biopharmaceutical compounds on the horizon", said Dr Syrmalis.*

About NASDAQ

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's



securities transactions. NASDAQ is home to more than 3,500 listed companies with a market value of over \$9.1 trillion.

Kelvin Boateng

Company Secretary

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with IQX's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE IQX Limited

IQX Ltd is a specialist life science investment and fund management organisation,

Sydney: 222 Clarence Street, Sydney, NSW 2000, Australia •Phone: +61 2 8239 5400 •Fax: +61 2 8362 9325

New York: 200 Park Avenue, Suite 1700, New York City, NY, USA 10166 •

London: 5 Harbour Exchange, Harbour Exchange Square, Canary Wharf E14 9GE UK•